✦ LIBER ✦

T.O.1 RNAi therapy for LGMD1A

✍ Scribed by Liu, J.; Wallace, L.M.; Garwick-Coppens, S.E.; Hauser, M.E.; Mendell, J.R.; Harper, S.Q.

Book ID: 119333964
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 50 KB
Volume: 22
Category: Article
ISSN: 0960-8966
DOI: 10.1016/j.nmd.2012.06.338

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

RNAi or overexpression: Alternative ther

RNAi or overexpression: Alternative therapies for Spinocerebellar Ataxia Type 1

✍ Keiser, Megan S.; Geoghegan, James C.; Boudreau, Ryan L.; Lennox, Kim A.; Davids 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 936 KB

RNAi for research and therapy

✍ Michael A Goldman 📂 Article 📅 2004 🏛 BioMed Central 🌐 English ⚖ 55 KB

P.O.3 Molecular pathogenesis of caveolin

P.O.3 Molecular pathogenesis of caveolinopathy in a mouse model of LGMD1C

✍ Y. Sunada; Y. Ohsawa; H. Hagiwara; N. Naoe; Y. Kuroda; T. Kawase; T. Murakami 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 45 KB

RNAi-directed inhibition of DC-SIGN by d

RNAi-directed inhibition of DC-SIGN by dendritic cells: Prospects for HIV-1 therapy

✍ Madhavan P. N. Nair; Jessica L. Reynolds; Supriya D. Mahajan; Stanley A. Schwart 📂 Article 📅 2005 🏛 American Association of Pharmaceutical Scientists 🌐 English ⚖ 330 KB

Harnessing RNAi nanomedicine for precisi

Harnessing RNAi nanomedicine for precision therapy

✍ Peer, Dan 📂 Article 📅 2014 🏛 River Publishers 🌐 English ⚖ 918 KB

T.I.1 Targeted therapies for myotonic dy

T.I.1 Targeted therapies for myotonic dystrophy

✍ Thornton, C. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 58 KB